Health Care

Attention Seeking Stock: Assembly Biosciences, Inc. (NASDAQ: ASMB)

0 3

On Wednesday, Assembly Biosciences, Inc. (NASDAQ: ASMB) signaled red -0.33% in trading session and finally closed at $39.45. The firm after opening the first trading session at $39.77 Over the one year trading period, the stock has an above price of $67.36 and it’s below is recorded at $18.60. The company has a market cap of $810.725M. The company most recent volume stood at 169,886 shares as compared to its average volume of 203,853 shares.

Assembly Biosciences, Inc. (NASDAQ: ASMB) stated financial results for the first quarter ended March 31, 2018.

First Quarter Financial Results

Cash, cash equivalents and marketable securities were about $109.2M as of March 31, 2018 contrast to about $123.3M, which included $3.3M of long-term marketable securities, as of December 31, 2017.

Revenues consisting of revenue from collaborative research were about $3.6M for the three months ended March 31, 2018, contrast to about $0.7M for the same period in 2017. The increase in revenue was Because of a raise in Allergan-related activities and expense reimbursement.

Research and development expenses were about $14.5M for the three months ended March 31, 2018, contrast to about $10.6M for the same period in 2017. This increase was primarilyBecause of increases in headcount across both the HBV and microbiome programs and ramp-up in HBV program expenses related to the predictable Phase 2a clinical studies to be initiated  in summer 2018.

The average true range of Assembly Biosciences, Inc.’s (ASMB) is recorded at 2.46 and the relative strength index of the stock stands 37.74. The stock price is going above to its 52 week low with 112.10% and lagging behind from its 52 week high with -41.43%. Analyst recommendation for this stock stands at 2.00. A look on the firm performance, its monthly performance is -7.85% and a quarterly performance of -17.05%. The stock price is trading downbeat from its 200 days moving average with -9.75% and down from 50 days moving average with -8.60%.

General and administrative expenses were about $5.7M for the three months ended March 31, 2018, contrast to about $4.0M for the same period in 2017. This increase was primarily Because of increases in headcount across the organization.

Net loss attributable to ordinary stockholders was about $16.2M, or $0.80 per basic and dilulted share, for the three months ended March 31, 2018, contrast to about $13.9M, or $0.81 per basic and diluted share for the same period in 2017.

Assembly Biosciences, Inc.’s (ASMB) has price-to-cash ratio of 7.61 and price to sale ratio of 69.78. The company net profit margin is # ref and gross profit margin is # ref. A look on the firm performance, its monthly performance is -7.85% and a quarterly performance of -17.05%. The stock price is moving down from its 20 days moving average with -10.09% and isolated negatively from 50 days moving average with -8.60%.

About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.

Newsletter